Cellular xenotransplantation of animal cells into people: benefits and risk by Scobie, Linda et al.
Cellular xenotransplantation of animal cells into people: benefits and risk
Scobie, Linda; Galli, Cesare; Gianello, Pierre ; Cozzi, Emanuele; Schuurman, H.-J.
Published in:







Link to publication in ResearchOnline
Citation for published version (Harvard):
Scobie, L, Galli, C, Gianello, P, Cozzi, E & Schuurman, H-J 2018, Cellular xenotransplantation of animal cells
into people: benefits and risk. in Scientific and Technical Review. vol. 37, OIE, pp. 113-122.
https://doi.org/10.20506/rst.37.1.2744
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
Take down policy
If you believe that this document breaches copyright please view our takedown policy at https://edshare.gcu.ac.uk/id/eprint/5179 for details
of how to contact us.
Download date: 29. Apr. 2020
Rev. Sci. Tech. Off. Int. Epiz., 2018, 37 (1), ... - ... 
SCOBIE_forPB33  1/21 
Cellular xenotransplantation of animal cells 
into people: benefits and risk 
L. Scobie 
(1)*
, C. Galli 
(2)
, P. Gianello 
(3)







School of Health and Life Sciences, Glasgow Caledonian 
University, Glasgow G4 0BA, United Kingdom
 
(2) Avantea, Via Porcellasco, 7/F, 26100, Cremona, Italy 
(3) Université Catholique de Louvain, Place de l'Université 1, 1348 
Louvain-la-Neuve, Belgium 
(4) Consortium for Research in Organ Transplantation (CORIT), 
Padua, Italy 
(5) Padua University Hospital, Via Giustiniani, 2 – 35128 Padua, 
Italy 
(6) SchuBiomed Consultancy BV, Frederik Hendrikstraat 81, 3583 
VH Utrecht, The Netherlands 
*Corresponding author: linda.scobie@gcu.ac.uk 
Summary 
The main benefit of xenotransplantation is its potential to overcome 
the worldwide organ shortage experienced in allotransplantation. 
Allogeneic transplantation is the only successful therapy for several 
life-threatening diseases, with cell, tissue or organ donation only 
partially meeting the demand and many patients dying while waiting 
for treatment. With supply falling short of demand, it is forseen that 
the use of porcine material may at some stage overcome the existing 
gap between organ availability and clinical need. Recently, pig islet 
cells have been utilised in clinical trials, with safety being 
demonstrated. Indeed, pig-derived cells present several advantages: i) 
porcine cells have a stable function and differentiation pattern and are 
not tumorigenic; ii) pig cells have been shown to meet the 
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physiological needs in large animal models; iii) the source of pig cells 
can be scaled-up to meet demands in a highly standardised manner, 
and with respect to animal welfare regulations; iv) designated-
pathogen-free (DPF) pig lines can be produced, which could result in 
a higher safety profile than allotransplantation itself; v) the risk of 
zoonosis, which was raised years ago as the major hurdle, has been 
recently circumvented and is actually viewed as a controlled risk; and 
vi) immune risks are being circumvented via the use of genetically 
modified donor animals and encapsulation of porcine cells, 
particularly for the treatment of diabetes. Overall, the benefit appears 
to outweigh potential risks with respect to cellular xenotransplantation 
and this is discussed further in this review. 
Keywords 
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Background 
Transplantation represents the ideal treatment option for many patients 
in terminal organ failure. Indeed, it has been clearly demonstrated that 
transplantation is associated with improved quality of life, extended 
patient survival, and reduced costs to society. However, 
transplantation is severely limited by a tremendous organ shortage 
and, as a consequence, benefits only a minority of patients. Most 
patients must continue with ongoing, expensive treatment. For 
instance, worldwide, over two million people affected by chronic 
kidney disease currently receive treatment with dialysis (instead of a 
transplant) to stay alive, with an overall cost of around 80 billion 
euros per year. Likewise, it is estimated that the total worldwide 
number of type 1 diabetic patients regularly injecting insulin is 
between 10 and 20 million (1). 
In light of this, it is of the utmost importance to identify novel sources 
of organs, tissues or cells to satisfy the clinical need. In this context, 
xenotransplantation, or transplantation of organs, cells or tissues 
between individuals belonging to two different species, such as from 
animals into humans, represents a potential solution to meet this 
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critical need. Although the immediate benefits are clear, this line of 
biomedical research is increasingly reliant on the use of large animals, 
notably the pig, which raises a number of associated risks. A full 
assessment of these benefits and risks is required for the development 
and clinical application of xenotransplantation for the purpose of 
improving human health. Ethical requirements are high on the list of 
importance of scientific societies, policy-makers and international 
agencies such as the World Health Organization and are heavily 
embedded in the regulatory frameworks dealing with 
xenotransplantation (2, 3, 4). Indeed, ethical considerations are an 
integral part of any xenotransplantation practice, and experts in ethics 
have been, and still are, involved in these important issues and are 
contributing to the development and harmonisation of guideline 
policies (5). This, however, is not the purpose of this paper and will 
not be discussed further. 
Assessing benefits and risks 
The risk of infection 
Each innovative medicinal product carries its own risks when 
administered to a patient, and a xenotransplantation product is no 
exception. The first risk factor that attracted attention was the 
potential transmission of infectious agents to the recipient, with 
resulting disease. This is relevant in view of the fact that a 
xenotransplantation product comprises living xenogeneic 
cells/tissues/organs, which precludes the sterilisation procedure that is 
possible for drugs and biologicals. The microbial risk of 
xenotransplantation is similar to that of autologous and allogenic cell 
therapy products; however, due to the nature of the source material, 
i.e. non-human, it is deemed more complex, as it is not known how 
certain animal pathogens will respond in a human host environment. 
Among the first documents from regulatory agencies addressing this 
item was the Public Health Service Guideline on Infectious Disease 
Issues in Xenotransplantation issued in the United States in 2001 (6). 
Subsequently, the Guidance on Xenotransplantation issued by the 
Food and Drug Administration (in 2003 and recently updated in 2016) 
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(7), and the Guideline on Xenogeneic Cell-based Medicinal Products 
issued by the European Medicines Agency (EMA) in 2009 (8) have 
provided more details. These regulatory documents address products 
from any species transplanted to humans, but in the following 
discussion, the donor will be limited to the swine species because this 
is currently the generally accepted species for a xenotransplantation 
product. 
The microbial risks of a xenotransplantation product can roughly be 
divided into three main categories (7): 
– transmission of infectious agents that are pathogenic for humans but 
may not be pathogenic or even detectable in the source animal host 
– transmission of organisms that may not normally be pathogenic in 
humans but can become so in the immunosuppressed or 
immunocompromised individual 
– recombination or re-assortment of infectious agents, particularly 
viruses, with non-pathogenic or endogenous human infectious agents, 
to form new pathogenic entities. 
These categories, however, do not mention infectious agents that are 
pathogenic for swine and can cause swine disease. 
Concerns about the microbial safety risk of using pigs in 
xenotransplantion were raised when there were reports of pig-to-
human transmission of porcine endogenous retrovirus (PERV) (it 
should be emphasised that clinical trials at that time were not 
discontinued, but only put on hold awaiting the development and 
implementation of monitoring protocols) (9). Subsequently, the initial 
concerns about the human tropism of PERV developed into a more 
general concern about a wider range of pathogens, including 
exogenous infectious agents, in particular, porcine viruses. This 
concern about transmission of infectious agents from donor to human 
recipients has resulted in the use of a new designation, namely 
‘designated-pathogen-free’ (DPF). (It is important to note that DPF 
does not mean that animals are gnotobiotic, i.e. devoid of any 
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infectious pathogen in all body compartments, including the 
alimentary tract; such a status is even more complicated to achieve in 
sustained production than the DPF status. Also, endogenous pathogens 
such as PERV are not included in the DPF status simply because of 
their endogenous presence.) 
Like the designation ‘specific-pathogen-free’ (SPF), which is widely 
used in biomedicine, DPF designation is not associated with a single 
prescribed list of pathogens that should not be present in the donor 
animals. Instead, pathogen exclusion lists, which should be presented 
and agreed with regulatory agencies, are proposed by the regulator, 
scientific community (10) and also by institutions preparing for 
clinical trials (11, 12). These lists may differ between continents and 
between countries, depending on the infectious agents that are present. 
There may also be different lists required for different 
xenotransplantation products, depending on the organ and tissue 
distribution of infectious agents and the processing of the organs or 
tissues before being administered to patients (13). 
Achieving the biosecurity barrier needed to achieve DPF status 
requires special conditions of breeding and husbandry (7, 14, 15). The 
most relevant factors to consider in maintaining a barrier to disease 
and preserving the health status of the animals are the building, the 
location, feed, staff, and the number of animals. The number of 
animals within the biosecure barrier should not only be sufficient for 
production of donors in, for example, clinical trials, but also be 
sufficient to avoid inbreeding in outbred animal herds. In general, the 
operations in the animal facility should be in compliance with the 
Good Manufacturing Practices employed in similar fields. Also, 
accreditation by the Association for Assessment and Accreditation of 
Laboratory Animal Care (www.aaalac.org) is recommended. 
From a risk perspective, there should be a programme for regular 
monitoring of the infectious agents on the agreed list of pathogens to 
be excluded. The frequency of sampling (blood, secretions or faeces) 
from the donor animals or of detailed investigation of sentinel 
animals, depends on the health status of the herd after its initial 
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population and the emergence and management of infection or disease 
outbreaks. Under high-hygiene biosecure conditions, DPF status can 
usually be achieved without the need for vaccination, and the use of 
antibiotics can be avoided. 
It is evident from the above that meeting the requirements for DPF 
status translates into a costly enterprise. In the US context, this could 
easily increase the price fifty-fold for one individual young-adult pig 
(six months old), which makes it impossible to produce for high-
volume administration. However, the basic question of whether or not 
there is indeed the need for expensive biosecure facilities for donor 
animals for a xenotransplantation product, i.e. medical-grade pigs, 
remains unanswered. Similarly, it is unclear whether the long storage 
periods recommended in regulatory documents governing sampling 
and the archiving of samples from the donor and recipient are 
justified. These documents recommend storage in a deep-frozen state 
for a long time, i.e. 30–50 years, but there is no rationale given for this 
instruction, except for one statement in the Public Health Service 
Guideline in the United States, which indicates that the requirement 
for long storage periods is based on ‘the latency periods of known 
human pathogenic persistent viruses and the precedents established 
by the US Occupational Safety and Health Administration with 
respect to record-keeping requirements’ (2). This indicates that the 
requirement for archiving is essentially a public health issue. It should, 
therefore, receive attention from not only the sponsor of clinical trials 
and the institution marketing the product, but also the governmental 
institutions overseeing public health. The issue falls outside the remit 
of the usual interactions between these parties and should be a 
separate item of discussion. This discussion should also address 
aspects such as the public/private sponsoring of archiving, ownership 
of the archive, and access to the archive. 
It is clear that it is important to discuss the requirements for archiving 
and, as stated above, it is equally important to question whether a 
barrier facility is really necessary for all types of xenotransplantion. 
Not having to maintain a biosecure barrier would significantly reduce 
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the cost risks. The following points are worth noting when considering 
whether or not such a barrier is necessary: 
– Caesarian sectioning and colostrum deprivation of the first 
population in an SPF-like facility may be sufficient (14). In other 
words, the building and operations are under less strict conditions than 
they would be if DPF status were required. An example is the facility 
for minipigs run by Ellegaard-Göttingen in Denmark (16, 17). 
– A proper selection of founder animals in facilities with high hygiene 
standards could serve the same purpose. A requirement for such 
facilities is that they be siutated in remote locations so as to avoid 
potential entry of pathogens from the environment. 
– Barriers other than physical barriers could serve to establish a DPF 
status. An example is the placenta, in the case that newborn piglets are 
used as the donor. In this case, the sows should be monitored during 
pregnancy for pathogens and virus activation, which can result in 
transmission through the placenta. 
– To assist with the costs associated with barrier facilities, some 
xenotransplantation products could be subject to a restricted pathogen 
exclusion list if, for example, distinct cells or tissues lack infection 
with specific viruses of concern. Cell products that are encapsulated 
before implantation could also be subject to a restricted list, as 
discussed in the recently published update of the consensus statement 
on conditions for undertaking clinical trials of porcine islet products in 
type 1 diabetes (8, 18). 
– The processing of tissue and organs and the time period of 
processing should also be considered. This particularly applies to 
some cell therapy products that require a long period of culture after 
cell isolation or establishment of cell lines before the product is 
released for administration. In this situation the microbial presence in 
the pig is quite remote from the final product (11, 13). 
It thus appears that a high-hygiene biosecure barrier might not be 
necessary in all cases of a xenotransplantation product. Hence, instead 
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of concentrating on intense husbandry conditions and animal herd 
monitoring, the focus could shift to detailed pathogen screening of the 
product before it is released. In this discussion, it should be noted that 
there is almost no information on how the microbial status of a donor 
relates to pathogen transmission and the development of disease in the 
host, although we do have some recent work demonstrating a lack of 
correlation betweeen the donor and tissue microbial status (19). It has 
been proposed that some exogenous pathogens that can be transmitted 
by pigs, such as hepatitis E and viruses in the herpes family (e.g. 
lymphotropic herpes viruses and cytomegalovirus) do pose a 
xenozoonotic risk (20), but the basic question of whether or not a 
xenotransplantaion product poses an infectious risk has not been 
answered definitively. At the moment, the assessment of microbial 
safety is mostly limited to animal models used for the purposes of 
testing the efficacy of xenotransplantation products, which are not 
always suitable. 
It is quite understandable that, considering the many unknowns 
regarding potential infection of a recipient of a xenotransplantation 
product by the product itself, regulatory agencies, in a risk-aversive 
approach, require donor animals to be devoid of any infectious 
pathogen. But studies, as well as many trials with/without regulatory 
oversight on living porcine products administered to humans, have, to 
date, not shown indications for pig-to-human pathogen transmission. 
Essentially, all the studies conducted to date suggest that a porcine 
xenotransplantation product is well tolerated and fairly safe, including 
from a microbial standpoint (12, 21, 22, 23). It has also been noted in 
the literature that the risk from PERV may no longer be as significant 
as initially perceived (24, 25, 26). 
Thus, it is tempting to conclude that, with the suggested strategies in 
place, xenotransplantation products will have a much better pathogen 
safety profile than the allogeneic living organs, tissue and cell 
preparations that are currently used in clinical practice. Selection of 
donors meeting high-quality health standards, and implementation of 
rigorous quality control to monitor organ and ischemia damage during 
procurement, transport and processing, are of high importance. So, at 
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least in theory, the ultimate risk–benefit ratio of a xenotransplantation 
product is expected to be much higher than that of a human-derived 
allogeneic product. 
At this point, it is worth providing further explanation of the word 
‘risk’. In many operations and industrial product manufacturing, and 
in regulatory documents, this word receives detailed attention. It is not 
only a question of ‘risk’, but of managing the risk. The regulatory 
agencies of the European Union, Japan and the United States 
recommend the adoption of the Quality Risk Management (QRM) 
guideline issued in 2005 by the International Conference on 
Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (27). Essentially, the ‘risk’ approach 
is separated into various steps in a continuous process which includes 
risk assessment (identification, analysis, and evaluation), followed by 
risk control (reduction and acceptance), and finally risk review. Both 
the evaluation of individual infectious agents and the evaluation of the 
product manufacturing process are expected to not only facilitate the 
discussion between sponsors and regulatory agencies, but also to 
facilitate the development of xenotransplantation products by 
improving the process of transforming research material into a product 
for clinical administration. 
Risks posed by clinical applications 
Cell replacement therapies represent innovative alternative treatments 
offering the promise of long-lasting restoration or amelioration of 
disrupted cellular functions rather than temporary alleviation of 
clinical symptoms necessitating lifelong medication. Patients suffering 
from degenerative and auto-immune diseases could benefit from such 
treatments. Pancreatic islet allotransplantation for the treatment of 
type I diabetes is a clinical reality, the transplantation of other cell 
types, such as hepatocytes, bone marrow or umbilical cord stem cells, 
is also a reality in the clinic today, and neural cell transplantation is in 
the early development stage (28, 29, 30). However, and regardless of 
tissue-specific considerations and difficulties, a common major 
obstacle standing in the way of widespread use of cell transplantation 
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is the lack of human donors, and this has led to the search for 
alternative sources of cells from other species. In this context, pigs 
have emerged as suitable candidates for providing xenocells due to 
anatomical and physiological similarities with humans. In the case of 
treatment for type I diabetes, porcine islets could meet the demand and 
have several advantages, including the functionality of porcine insulin 
in humans due to high similarity in protein sequence, which supports 
the case for using pigs as a donor species (reviewed in [31, 32]). 
Moreover, it is possible to genetically modify donor pigs to mitigate 
the host immune reaction to xenografted cells and to adapt their 
function to human physiology when needed, which will definitely 
accelerate the transition of cell xenotransplantation from the bench to 
the clinic. The first exploratory health economic evaluation of a 
porcine islet xenogenic cell therapy product showed that this product 
may prove to be a cost-effective and possibly cost-saving procedure 
for type 1 diabetes compared to standard management using insulin 
treatment, even thought the costs per pig are quite high (33). 
Regarding methods of delivering islets into the recipient, the methods 
currently preferred are: intra-portal transplantation, as performed in 
allotransplantation, for free porcine islets (wild-type or genetically 
modified); extra-peritoneal implantation for macroencapsulated 
islets; intraperitoneal implantation for microencapsulated islets; and 
subcutaneous implantation for macroencapsulation devices. 
Intramuscular implantation of free islets is also currently under 
investigation (28, 34, 35, 36). However, the free transplantation of 
such non-encapsulated cell sources, in humans, is not yet permitted 
by the EMA due to possible transfer of pathogens and because of the 
risk of uncontrolled cell replication in the recipient organism, although 
a recent study demonstrated a lack of pathogen transmission to 
marmosets (23). 
Another limitation of cell transplantation is the need for 
immunosuppression. Allo- or xeno-transplantation of insulin-secreting 
cells in humans is possible, but it elicits a severe immune rejection 
requiring immunosuppressive treatment of the recipient. This 
treatment, although beneficial in preventing islet rejection, has 
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significant side effects, such as diminishing islet function or induction 
of islet death, kidney toxicity and diabetogenicity. Immune isolation 
of cells by encapsulation is a promising strategy for both allogenic 
and xenogeneic cell transplantation. This avoids lifelong 
immunosuppression and should be readily implemented in the clinic. 
Permselective membranes protect the transplanted cells against the 
recipient’s immune system, but allow oxygen and nutrient supply 
(reviewed in [37]). There are still major immunological obstacles to 
successful clinical islet xenotransplantation, but strategies to 
overcome these have been developed. Some genetic modifications, 
e.g. elimination of proinflammatory molecules or insertion of 
transgenes to improve survival and function, may also be beneficial 
for encapsulated islets (31). Alternatively, human beta-cells can be 
produced from pluripotent stem cells. Their delivery route strategy is 
similar to that described above, as avoidance of immune rejection of 
allogenic donor cells follows the same logic. In theory, use of 
patient-derived induced pluripotent stem cells (iPSCs) would allow for 
autologous beta-cell production and transplantation. However, this is 
considered an economically non-viable option at the moment due to 
the current technological limitations. 
A number of clinical xenotransplantation trials in humans have 
already been described in the literature and deemed safe (12, 13, 22). 
Efficacy confirmation requires further research; however, in the 
context of islet cells, the risk is considered low. 
Risks posed by genetic modification 
Cutting edge research is dependent on genetic engineering/genome 
editing for the purpose of creating suitable surrogates for the study of 
genetic diseases (38, 39, 40, 41) and regenerative medicine (42), or for 
supplying an unlimited source of cells, tissues, organs and scaffolds 
that can be used effectively and safely for transplantation to cure 
human diseases (43). Multi-transgenic pigs have already been 
generated by classical means of homologous recombination and/or 
random integration. The development of GGTA1-KO pigs was a 
fundamental step in reducing the risk of immune rejection in 
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xenotransplantation. Now, multiple transgenes can be introduced on a 
donor genetic background, not only to mitigate immune complications 
but also to improve the function and production of insulin (44). With 
the use of programmable nucleases, multiple recombination events 
(ins/del or homology directed repair) can be obtained in one single 
step. Targeted integration can ensure the optimal performance of any 
transgene integrated, therefore increasing the efficacy of the expected 
function. 
To date, the multi-transgenic pigs generated by conventional means 
for xenotransplantation are healthy and can reproduce. However, 
unexpected phenotypes can develop after repeated rounds of multiple 
genetic engineering, vital function can be affected, and side effects 
due to inadequate transgene function can occur. With genome editing, 
the same concerns may arise, but the precise genetic modification that 
can be obtained should be of less concern. Genome editing technology 
has significantly evolved since the initial reports (43). Accordingly, 
recent work has demonstrated remarkable survival rates. For example, 
in baboons, the use of transgenic pigs for heterotopic cardiac 
xenografts, coupled with an aggressive immunosuppression regimen, 
resulted in post-transplantation survival rates of up to almost three 
years (45). 
Progress in the field of xenotransplantation has changed gear since 
nuclease-based techniques have been implemented for editing the pig 
genome (46, 47, 48, 49). The number of transgenic animals with 
inactivated genes and/or integrated novel transgenes has dramatically 
increased, thus facilitating the development and completion of pre-
clinical studies (40, 41, 42, 50, 51, 52, 53, 54). Genome editing in live 
pigs is required to test the safety and efficacy of this technology for 
xenotransplantation products. Although potential off-target effects are 
often indicated as possible complications, animals generated after 
genome editing do not appear to be different from those generated by 
conventional technologies. Therefore, there are no fundamental 
reasons why genetically modified pigs utilising gene editing pose a 
priori different risks compared with those engineered by conventional 
Rev. Sci. Tech. Off. Int. Epiz., 37 (2) 13 
SCOBIE_forPB33  13/21 
transgenesis. However, risks should be carefully assessed case by case 
depending on the modified/added genes. 
Finally, PERV has been the main focus of concern in gene editing due 
to their presence as integrated elements in the pig genome, but recent 
work using CRISPR/Cas9 technology has convincingly demonstrated 
that multiple copies of PERV can be targeted simultaneously to obtain 
PERV-free cells (55). However, it is yet to be demonstrated that this 
technology can give rise to healthy animals. 
Conclusion 
It is clear that the use of xenotransplantation to treat human disease 
would be of great benefit but can pose a risk. However, it is also clear 
that many of these risks can be overcome with careful consideration 
and planning. The future of clinical xenotransplantation is particularly 
bright with respect to the use of porcine cells and their use should be 
supported as an alternative to current methods. 
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